Olpasiran (AMG 890, ARC-LPA) sodium is an N-acetyl galactosamine (GalNAc)-conjugated, hepatocyte-targeted siRNA. Olpasiran sodium directly inhibits LPA messenger RNA translation in hepatocytes and potently reduce Lp(a) concentration. Olpasiran sodium can be used for the research of cardiovascular disease, such as atherosclerosis[1][2].
Molecular Weight:
15438.7 (free acid)
Purity:
98.82
Formula:
C490H610F11N164Na42O306P41S7
Target:
Small Interfering RNA (siRNA)
Application Notes:
MCE Product type: Oligonucleotides
* VAT and and shipping costs not included. Errors and price changes excepted